Cellular Therapy
News
FDA investigates secondary cancers from CAR T-cell therapies
The agency is evaluating the need for regulatory action on the links between CAR T-cell immunotherapies and secondary blood cancers.
Conference Coverage
T-cell cancers: CAR T therapy to the rescue?
Trials are small and incomplete, but CAR T-cell therapy has yielded promising early results in treating T-cell blood cancers.
Conference Coverage
DLBCL treatment options: CAR T outperforms ASCT
Relapsed and refractory DLBCL patients treated with CAR T-cell therapy achieved better outcomes than with autologous stem cell transplants.
Conference Coverage
Frontline myeloma treatments: ASCT vs. CAR T
Experts debate whether CAR T-cell therapy could eventually replace autologous stem cell transplant (ASCT) as the standard of care for multiple...
Feature
Dispelling clinicians’ misconceptions about sickle cell disease
Among clinicians and their patients, widespread myths about sickle cell disease can stand in the way of adequate treatment.
News
FDA approves motixafortide for stem cell mobilization in myeloma
Motixafortide has been approved by the FDA to help mobilize hematopoietic stem cells in autologous transplants for patients with multiple myeloma...
Conference Coverage
Is additional treatment needed, pretransplant, for r/r AML?
The issue of whether or not patients with r/r AML require additional treatment pretransplant was debated at SOHO 2023.
Feature
‘Promising’ new txs for most common adult leukemia
The FDA has already approved these treatments for some other blood cancers, but chronic lymphocytic leukemia (CLL) poses unique challenges.
Conference Coverage
SCD, beta-thalassemia: CRISPR-based gene therapy `transformative’
Phase 3 results suggest potential for a “functional cure”; this treatment could become first-ever approved CRISPR gene-editing therapy.
From the Journals
ESMO helps hematologists assess new cancer drugs
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.